Paratek Pharma

Boston, United States Founded: 1996 • Age: 30 yrs Listed Acquired By Gurnet Point Capital
Therapeutics for antimicrobial resistant infections are developed.

About Paratek Pharma

Paratek Pharma is a Healthcare company based in Boston (United States) founded in 1996, and was acquired by Gurnet Point Capital in June 2023. Therapeutics for antimicrobial resistant infections are developed. Paratek Pharma has raised $96.48 million across 11 funding rounds from investors including Hercules Capital, HHS and Abingworth. The company has 205 employees. Paratek Pharma has completed 2 acquisitions, including OptiNose and Transcept Pharmaceuticals. Its chief executive, as recorded, is Michael Bigham. Paratek Pharma offers products and services including NUZYRA. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Paratek Pharmaceuticals, Inc. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.

  • Headquarters Boston, United States
  • Employees 205
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website paratekpharma.com
  • Social LinkedIn X
  • Acquired by Gurnet Point Capital (Jun 2023)
  • Legal Name Paratek Pharmaceuticals, Inc.
Operational Areas
Key Metrics

Products & Services of Paratek Pharma

Paratek Pharma offers a comprehensive portfolio of products and services, including NUZYRA.

NUZYRA
Antibiotic

FDA-approved tetracycline-class drug for treating bacterial infections.

Funding Insights of Paratek Pharma

Paratek Pharma has successfully raised a total of $96.48M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $96.48M
  • Total Rounds 11
  • First Round $36M

    (Nov 2002)

  • Investors Count 17

Latest 10 of 11 funding rounds of Paratek Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2021Grant––
Apr 2018$160MPost-IPO––
–
Jun 2016$59.7MPost-IPO––
–
May 2015$71.1MPost-IPO––
–
Jul 2014$93MPost-IPO––
–
Jun 2014$93MPost-IPO––
Dec 2008$3.15MGrant––
Oct 2007$40MPost-IPO––
Jan 2006$25.43MSeries B––
–
Jan 2004$35.05MSeries B––
–
Valuation history

19 investors in total: 19 institutional.

Investors in Paratek Pharma

Paratek Pharma has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, HHS and Abingworth.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early stage venture capital firm investing in US
1973abingworth.comLondon, United Kingdom
PE firm investing in the US
aislingcapital.comNew York, United States
Life sciences focused VC firm funding companies in the US and Europe
2001hbmhealthcare.comZug, Switzerland
Early-stage investing in IT and healthcare ventures.
interwest.com
Venture capital firm
omegafunds.comBoston, United States
Investments are made in innovative life science companies globally.
nvfund.comBasel, Switzerland
Venture capital investments are made in innovative healthcare companies.
phase4-partners.comLondon, United Kingdom
Venture debt financing is provided to companies in multiple sectors.
2003htgc.comPalo Alto, United States
biovedavc.com
A center dedicated to supporting biotech innovators in Louisiana.
neworleansbio.comNew Orleans, United States
Premium access

Investor details for Paratek Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Paratek Pharma

161 people are tracked at Paratek Pharma (60 in leadership, 4 in board & advisors, 97 in team); the tracked headcount is 205.

NameRoleGroup
Michael Bigham
CEOLeadership
Jared Emerson
Director, Business InsightsLeadership
Ben Novak
Senior Director Of Government AffairsLeadership
Adam Woodrow
President & Chief Commercial OfficerLeadership
Karen McGrath
Chief People OfficeLeadership
Liron Sissman
Vice President, Business DevelopmentLeadership
Cathleen F.
Associate Director, Sales TrainingLeadership
Kristen Manion
Vice President Regulatory Affairs Quality And ManufacturingLeadership
Patricia R.
Senior Director, Sales Training And DevelopmentLeadership
Nicole McCann
Regional Business Director, Western Tri-state (pa, Ny, Nj)Leadership
David Brown
Regional Business Director- Specialty SalesLeadership
Jeanette Straus
Associate Director Field Reimbursement And Patient ServicesLeadership
Alisa Serio
Executive Director, Microbiology And Nonclinical DevelopmentLeadership
Jody McGuffee
Regional Business Director Bayou RegionLeadership
Katie Zitoli
Vp, Finance & ControllerLeadership
Rose Dileo Snyder
Director, Quality AssuranceLeadership
Diane Anastasiou Mt
Director, MicrobiologyLeadership
Sean Kelly
Regional Business Director Northeast And Mid AtlanticLeadership
Jason Boehmer
Executive Director, National SalesLeadership
Michele O'Leary
Regional Business Director - Pacific NorthwestLeadership

141 more people are available in the full profile.

Premium access

Complete people profiles for Paratek Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Paratek Pharma

Paratek Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OptiNose and Transcept Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Developer of smart devices for nasal drug delivery
optinose.comMorrisville, United States2000Mar 2025$330M
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions
transcept.comBoston, United States1996Jul 2014••••
Premium access

Complete acquisition details for Paratek Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Paratek Pharma

7 dated milestones of Paratek Pharma across 29 years, from founding to its latest funding, stage changes and deals.

  1. Founded Paratek Pharma is founded.
  2. Funding First funding round of $36.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Transcept Pharmaceuticals.
  5. Funding Latest funding round, Grant,.
  6. Exit Acquired by Gurnet Point Capital.
  7. Acquisition Acquires OptiNose.

Competitors of Paratek Pharma

Paratek Pharma has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sperotherapeutics.com2013Cambridge, United States$114.7M46
Therapeutics for drug-resistant bacterial infections are developed.
melinta.com2000Morristown, United States$186M290
Developer of bacterial ribosome-targeting drugs for MDR infections
aphage.com2016Bethesda, United States$107.87M78
Therapies for multi-drug resistant infections are developed using bacteriophages.
Premium access

Detailed competitors of Paratek Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Paratek Pharma

The website of Paratek Pharma (paratekpharma.com) receives about 4K visits a month and ranks #5,533,702 among all websites worldwide, #6,125 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4K

    ▲ 33.4% vs previous month

  • Unique visitors
    1.3K

    per month

  • Global rank
    #5,533,702

    among all websites

  • Category rank
    #6,125

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Paratek Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
praxismedicines.com
100%
35.6K#1,244,570View details
servier.us
100%
#2,050,491View details
ensoma.com
100%
2.8K#4,644,561View details
pieris.com
99%
View details
cellarity.com
95%
5.8K#2,884,812View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 16 similar websites and full traffic analytics for Paratek Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Infectious Diseases

3 companies that operate in the same segment as Paratek Pharma (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Paratek Pharma

Premium access

Complete news archive for Paratek Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Paratek Pharma

Paratek Pharma was founded in 1996 and raised its 1st funding round 6 years after it was founded.

Paratek Pharma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Michael Bigham is the CEO of Paratek Pharma, as recorded in our data.

Paratek Pharma is a funded company, having raised a total of $96.48M across 11 funding rounds to date. The company's 1st funding round was a Series B of $35.05M, raised on Nov 2002.

Paratek Pharma has 205 employees.

Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.

Paratek Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.

Paratek Pharma offers NUZYRA.

Paratek Pharma has made 2 acquisitions, including OptiNose, and Transcept Pharmaceuticals.

Paratek Pharma has 19 investors. Key investors include Hercules Capital, HHS, Abingworth, HBM Healthcare Investments, and Lombard Odier.

Paratek Pharma operates through Paratek Pharmaceuticals, Inc..

Yes. Paratek Pharma was acquired by Gurnet Point Capital in June 2023.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available